(70 days)
The AF Laser device is indicated for use for the temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes Trichophyton rubrum and T. mentagrophytes, and/or yeasts Candida albicans, etc.).
The AF Laser is a medical laser used to treat nail fungus (onychomycosis) and promote the growth of healthy nails. The operating mechanism of this device is photochemical reaction that uses two wavelengths -- 635nm and 405nm. The AF laser is a compact, all-in-one device that is intended to be used on the floor and is operated by an intuitive 10.2 inch's wide LCD screen for ease of use. An LCD monitor incorporated into the deck of the device helps the operator check the exact location of treatment area during a procedure.
This document describes the FDA's 510(k) clearance for the AF Laser, a device intended for the temporary increase of clear nail in patients with onychomycosis.
Based on the provided text, the acceptance criteria and study proving the device meets these criteria can be summarized as follows:
1. Table of Acceptance Criteria and Reported Device Performance:
The document states that the AF Laser is "substantially equivalent" to its predicate device, the LunulaLaser (K153164). The acceptance criteria appear to be met by demonstrating this substantial equivalence, rather than through specific performance metrics outlined in a dedicated clinical study against a predefined threshold.
| Acceptance Criteria (Implied by Substantial Equivalence Basis) | Reported Device Performance (Comparison to Predicate) |
|---|---|
| Indications for Use: Must be identical or similarly effective for the intended treatment. | Identical to LunulaLaser: "The AF Laser device is indicated for use for the temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes Trichophyton rubrum and T. mentagrophytes, and/or yeasts Candida albicans, etc.)." |
| Laser Wavelength: Must be comparable. | Identical to LunulaLaser: 405nm/635nm (±10%) |
| Output Energy: Must be comparable. | Similar to LunulaLaser: AF Laser: 405nm: 23mW ± 1.85mW, 635nm: 17mW ± 1.35mW LunulaLaser: 405nm: 23.00 ± 2.00mW, 635nm: 17.25 ± 1.25mW |
| Output Area: Must be comparable. | Identical to LunulaLaser: Line pattern electronically scanned over area of treatment. |
| Output Type: Must be comparable. | Identical to LunulaLaser: Constant Wave |
| Operating Time: Must be comparable. | Identical to LunulaLaser: 0-12 minutes (±5% with 1 minute increment for AF Laser, 0-12 minutes for LunulaLaser). |
| Safety Standards Compliance: Must comply with relevant safety standards. | Passed IEC 60601-1, IEC 60601-1-2, IEC 62471:2006, IEC 60825-1:2014. These are tests for basic safety, essential performance, electromagnetic compatibility, photobiological safety, and laser product safety. |
| General Technological Characteristics: Must be similar. | Similar in Dimension and Weight (minor differences noted). Identical in Screen type (LCD Touch Screen). |
2. Sample Size Used for the Test Set and the Data Provenance:
The document explicitly states: "No Clinical testing was conducted as part of this submission." Therefore, there is no test set of clinical data from human subjects in the traditional sense for evaluating device performance against acceptance criteria for clinical efficacy. The submission relies on a comparison to a predicate device and engineering/bench testing.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts:
Since no clinical testing was performed, there was no clinical test set requiring expert ground truth establishment.
4. Adjudication Method for the Test Set:
Not applicable, as no clinical test set was used.
5. If a Multi Reader Multi Case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
Not applicable. This device is a laser for direct treatment, not an AI-assisted diagnostic tool for human readers.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
Not applicable, as this is not a diagnostic algorithm. Performance was assessed through engineering and safety standards compliance, and comparison to the predicate device.
7. The Type of Ground Truth Used:
The "ground truth" for this submission appears to be the established safety and efficacy profile of the legally marketed predicate device (LunulaLaser K153164) and compliance with international safety and performance standards for laser devices.
8. The Sample Size for the Training Set:
Not applicable. As this is not a machine learning or AI device, there is no "training set."
9. How the Ground Truth for the Training Set Was Established:
Not applicable.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health and Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
July 20, 2022
ShenB Co Ltd % Connie Hoy Consultant Hoy and Associates 1830 Bonnie Way Sacramento, California 95825
Re: K221363
Trade/Device Name: AF Laser Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: PDZ Dated: May 10, 2022 Received: May 11, 2022
Dear Connie Hoy:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809 ); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Jianting Wang Acting Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K221363
Device Name AF Laser
Indications for Use (Describe)
The AF Laser device is indicated for use for the temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes Trichophyton rubrum and T. mentagrophytes, and/or yeasts Candida albicans, etc.).
| Type of Use (Select one or both, as applicable) | |
|---|---|
| X Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510K Summary AF Laser K221363
This 510(K) Summary of safety and effectiveness for the AF Laser is submitted in accordance with the requirements of the SMDA 1990 and following guidance concerning the organization and content of a 510(K) summary.
| Applicant: | ShenB Co Ltd. |
|---|---|
| Address: | Shenb Bldg 148Seongsui-roSeongdong-Gu, Seoul , KR 04796 |
| Contact Person: | Bora Kim |
| Contact Information: | kimbora@shenb.com+82-70-4814-2978 |
| Preparation Date: | July 11, 2022 |
| Device Trade Name: | AF Laser - K221363 |
| Common Name: | Lasers For Temporary Increase Of Clear Nail In Patients WithOnychomycosis |
| Regulation Name: | Laser surgical instrument for use in general and plasticsurgery and in dermatology |
| Regulation Number: | 21 CFR 878.4810 (Product Code: PDZ) |
| Legally Marketed Predicate Device: | LunulaLaser (K153164) |
| Regulatory Class: | Class II Prescription Use |
| Description of the AF Laser: | The AF Laser is a medical laser used to treat nail fungus(onychomycosis) and promote the growth of healthy nails.The operating mechanism of this device is photochemicalreaction that uses two wavelengths -- 635nm and 405nm.The AF laser is a compact, all-in-one device that is intendedto be used on the floor and is operated by an intuitive 10.2inch's wide LCD screen for ease of use. An LCD monitorincorporated into the deck of the device helps the operatorcheck the exact location of treatment area during aprocedure. |
| Intended use of AF Laser: | The AF Laser device is indicated for use for the temporaryincrease of clear nail in patients with onychomycosis (e.g.,dermatophytes Trichophyton rubrum and T.mentagrophytes, and/or yeasts Candida albicans, etc.). |
{4}------------------------------------------------
510K Summary
AF Laser
K221363
| Performance Testing | The following performance data was provided in support of the substantial equivalence determination: |
|---|---|
| IEC 60601-1 Test for Medical Electrical equipment was performed for General Requirements for basic safety and essential performance | |
| IEC 60601-1-2 Test for Medical Equipment for General Requirements for basic safety and essential performance: electromagnetic compatibility | |
| IEC 62471:2006 - Photobiological safety of lamps and lamp systems | |
| IEC 60825-1:2014 - Safety of laser products - Part 1: Equipment classification and requirements | |
| Clinical Testing | No Clinical testing was conducted as part of this submission. |
Substantial Equivalence Discussion
Predicate Device Manufacturer Information
| Proposed device | Predicate Device | |
|---|---|---|
| Device Name | AF Laser | LunulaLaser(K153164) |
| Manufacturer | ShenB Co., Ltd148, Seoungsui-roSeoungdong-guSeoul, Korea | Erchonia Corporation2021 Commerce DriveMcKinney, TX 75069 |
Indications for Use Comparison
| Proposed Device – AF Laser | Predicate Device- LunulaLaser | Comparison |
|---|---|---|
| The AF Laser device is indicatedfor use for the temporaryincrease of clear nail in patientswith onychomycosis (e.g.,dermatophytes Trichophytonrubrum and T. mentagrophytes,and/or yeasts Candida albicans,etc.). | The LunulaLaser™ device isindicated for use for thetemporary increase of clear nailin patients with onychomycosis(e.g., dermatophytesTrichophyton rubrum and T.mentagrophytes, and/or yeastsCandida albicans, etc.) | Identical |
{5}------------------------------------------------
510K Summary AF Laser K221363
| Specification | AF Laser -Proposed Device | LunulaLaser-Predicate Device | Comparison |
|---|---|---|---|
| LaserWavelength | 405nm/635nm (±10%) | 405nm/635nm (±10%) | Identical |
| Output Energy | 405nm: 23mW ± 1.85mW635nm: 17mW ± 1.35mW | 405nm: 23.00 ± 2.00mW635nm: 17.25 ± 1.25mW | Similar |
| Output area | Line pattern electronicallyscanned over area oftreatment | Line pattern electronicallyscanned over area oftreatment | Identical |
| Output Type | Constant Wave | Constant Wave | Identical |
| Operating Time | 0-12 minutes (±5%) with 1minute increment | 0-12 minutes | Identical |
| Dimension | 424mm(W) × 308mm(L) ×352mm(H) | 300mm(W) x 254mm (L) x400mm (H) | similar |
| Weight | 17.5kg | 10.43 kg | similar |
| Screen | LCD Touch Screen | LCD Touch screen | Identical |
Discussion
The ShenB AF Laser is identical to its predicate device, the Lunula Laser. They share indications for use, laser wavelengths, and the designs of the device treat patient toenails in the same way. The only difference is slightly different sizes and appearance of the device. Therefore, the ShenB AF Laser is substantially equivalent to the Lunula Laser.
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.